PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
 
J Clin Invest. Apr 1, 2008; 118(4): 1350–1353.
Published online Mar 20, 2008. doi:  10.1172/JCI35326
PMCID: PMC2268881
HOXB4 and retroviral vectors: adding fuel to the fire
Andre Larochelle and Cynthia E. Dunbar
Molecular Hematopoiesis Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Address correspondence to: Cynthia E. Dunbar, National Heart, Lung, and Blood Institute, Hematology Branch, Building 10CRC, Room 4-5132, 10 Center Drive, Bethesda, Maryland 20892, USA. Phone: (301) 496-1434; Fax: (301) 496-8396; E-mail: dunbarc/at/nhlbi.nih.gov.
Abstract
The transcription factor homeobox B4 (HOXB4) is a promising agent capable of providing a growth advantage to genetically modified hematopoietic stem and progenitor cells (HSPCs). In this issue of the JCI, Zhang and colleagues overexpressed HOXB4 in HSPCs from large animals using retroviral vectors (see the related article beginning on page 1502). Two years after transplantation, most animals developed leukemia, a consequence of combined HOXB4 and deregulated protooncogene expression. These results highlight the risks of combining integrating vectors and growth-promoting genes for clinical applications.
Hematopoietic stem and progenitor cells (HSPCs) are ideal targets for permanent genetic correction of defects in any lineage of hematopoietic cells. Most clinical applications have used gene transfer vectors based on integrating retroviruses, but the relative inefficiency of these vectors has limited the considerable potential of gene transfer into HSPCs. Genetically modified cells represent only a small fraction (1%–10%) of the hematopoietic cells after transplantation. Consequently, competition from unmodified infused and endogenous HSPCs may dilute any therapeutic effect of the transduced cells. This implies that this small fraction of genetically modified hematopoietic cells will correct diseases requiring more than 1%–10% of corrected cells only if they have a marked selective growth advantage in vivo.
In most diseases considered to be suitable targets for gene therapy, corrected cells do not themselves have an inherent growth advantage, providing an impetus to arm retroviral vectors with genes capable of conferring a selective growth advantage to transduced HSPCs and their progeny in vivo. Ectopic expression of homeobox B4 (HOXB4), a transcription factor containing a highly conserved DNA-binding motif known as the homeodomain, has been found to enhance HSPC self-renewal in vitro and in vivo and has been suggested as an approach not only to enhance gene therapy efficacy, but also in other clinical settings where the numbers of HSPCs are limited, such as cord blood transplantation.
The impact of HOXB4 expression on HSPC self-renewal was discovered by Sauvageau et al., who demonstrated that transfection of normal mouse bone marrow cells with a retroviral vector overexpressing HOXB4 resulted in a dramatic increase in engraftment ability and HSPC number compared with marrow transfected with a control vector (1). Importantly, the recipient mice did not develop hematopoietic abnormalities or malignancies, suggesting HOXB4-expressing HSPCs were still subject to normal homeostatic controls (2, 3). Since these initial studies, it has additionally been reported that HOXB4 can expand primitive human progenitors in culture as well as those human cells able to engraft immunodeficient mice (4, 5).
Despite these encouraging findings, investigators have worried that inclusion of HOXB4 in gene transfer vectors could carry significant risks, particularly in the context of evolving concerns regarding vector-related insertional mutagenesis (6, 7). The strong enhancers contained in retroviral genomes can activate adjacent cellular genes following integration, but the risk posed by one or a few integrated vectors per cell was estimated to be very low. However, these assumptions were shattered in 2002, when French researchers announced that a child who had shown unequivocal clinical benefit in the HSPC gene therapy trial for X-linked SCID (SCID-X) (8, 9) developed a vector-related T cell acute leukemia three years after infusion of retrovirally modified CD34+ cells (10). Since then, three other children in the French trial and, more recently, one patient in a similar SCID-X study conducted by British researchers have developed leukemias. In at least three cases, the tumor cells had a clonal vector insertion activating the LIM domain only 2 (LMO2) transcription factor gene (11). It was hypothesized that cooperation between LMO2 and the growth-promoting effect of the corrective IL-2 receptor γ (IL2RG) transgene resulted in leukemic transformation, perhaps limiting the problem to SCID-X (12). However, 2 patients with chronic granulomatous disease treated in an HSPC gene therapy protocol have developed abnormal hematopoiesis and clonal expansion of vector-containing cells due to activation of protooncogenes (e.g., MDS-EVI1), despite the lack of growth-promoting activity of the corrective transgene (13). Our group also reported the development of vector-associated myeloid sarcoma in a rhesus macaque five years following transplantation of HSPCs transduced with a vector containing only a marker gene and a drug-resistance gene (14).
It has been demonstrated that high-level HOXB4 expression, achieved with retroviral (5) or adenoviral (15) vectors in human CD34+ cells, perturbed the myeloid differentiation program both in vitro (5, 15) an in vivo (5) without frank leukemia. Similarly, disturbed myeloid differentiation was observed in a multipotent hematopoietic cell line in vitro (16). Ectopic HOXB4 expression also proved to be key in the production of primitive mouse hematopoietic cells from embryonic stem cells then able to engraft irradiated recipients; however, these mice had abnormal hematopoiesis with enforced myeloid and suppressed lymphoid development (17).
Despite these warning signs and continued concern regarding potential cooperativity between growth-altering transgenes and vector insertion sites, investigators continued to pursue the potential of the HOXB4 approach. In a study published in 2006, Kiem and his research group at the Fred Hutchinson Cancer Research Center reported preliminary results in their powerful non-human primate competitive repopulation model (18). They transduced monkey CD34+ cells with either a HOXB4-expressing vector or a control vector expressing only a marker gene and analyzed the competitive repopulating ability of these cells in vivo. As hoped, there was a very significant advantage for the HOXB4-transduced cells early following engraftment of the monkeys, but in contrast to mouse studies, a much less significant advantage for the HOXB4-transduced cells was observed long-term after transplantation (18).
In their study in this issue of the JCI, the same group now reports the first instances of leukemia linked to HOXB4 expression, both in the original group of monkeys now followed longer term and in dogs that received cells transduced with a HOXB4-expressing vector (19). Some 2 years after transplantation, 3 of 4 animals (2 of 2 dogs and 1 of 2 non-human primates) developed acute myeloid leukemias. Several lines of evidence strongly implicated HOXB4 in leukemogenesis. High-level HOXB4 expression was confirmed in the leukemic cells. Also, 3 of 4 animals followed long-term in this study developed leukemia, compared with none of more than 40 dogs and monkeys transplanted with cells transduced with similar vectors not expressing HOXB4 by the same research group and only 1 of 80 macaques followed long-term by our group (14). The most compelling evidence for the pivotal role of HOXB4 was provided by deriving a cell line from the leukemic cells of one animal and using short hairpin RNAs to knockdown HOXB4 expression in these cells. Profound growth inhibition and rapid cell death occurred with downregulation of the HOXB4 transgene.
Was HOXB4 expression sufficient as a single event to cause leukemia? To gain further insights, the authors localized vector integration sites in the genome (19). Interestingly, insertion sites in all tumors were near or within several protooncogenes, including c-myb and PRDM16 (already implicated in the chronic granulomatous disease trial described above), leading to aberrant expression of these genes. This suggests cooperativity between HOXB4 and the nearby activated protooncogenes, similar to the proposed cooperativity between LMO2 vector activation and the IL2RG transgene in the SCID-X trials. Overall, HOXB4 can be considered as a catalyst for leukemia development following retroviral gene transfer (Figure (Figure1). 1).
Figure 1
Figure 1
Development of leukemia after transplantation of HSPCs transduced with retroviral vectors.
This study underscores the importance of large animal models in further development of gene and other novel HSPC-directed therapies. Perhaps no leukemias linked to HOXB4 overexpression developed in mice because too few gene-modified HSPCs could be given to these small animals, much fewer than the number of transduced HSPCs transplanted in clinical trials or larger animal models. Or perhaps a long latency period, longer than the lifespan of a mouse, was required before evidence of leukemic transformation could be seen. HOXB4 or similar growth-promoting genes are not a sine qua non for the development of malignancies following HSPC gene transfer, but they appear to significantly increase the probability of such an event.
The message of the current study by Zhang and colleagues (19) is clear as a bell: overexpression of HOXB4 using integrating retroviral vectors is much too risky to be contemplated in any clinical settings. This is not to say that this study rules out alternative approaches to harnessing the power of HOXB4 on HSPCs. For instance, a soluble recombinant HOXB4 protein induced rapid ex vivo expansion of transduced HSPCs, thereby avoiding the use of integrating retroviral vectors while benefiting from the self-renewal capacity of HOXB4 (20, 21). However, the short half-life of the recombinant protein has proven a practical hurdle, and it remains unclear whether HOXB4 can expand human and primate long-term hematopoietic stem cells. Alternatively, HOXB4 may be transiently delivered to cells using nonintegrating retroviral vectors. “Suicide genes” such as herpes thymidine kinase could be included in vectors to provide the opportunity for delivering an exogenous “mission abort” signal via administration of ganciclovir if evidence for unchecked clonal growth appeared following gene therapy. However, killing efficiency is unlikely to be complete and, therefore, many problematic clones and subclones could persist after ganciclovir treatment.
Events in the recent history of gene therapy have led many to acknowledge that the field may have been, on several occasions, too eager to rush into the clinic. However, the wisdom gained from these setbacks is now becoming apparent in studies such as that of Zhang and colleagues in this issue of the JCI (19). Scientists and clinicians hoping to use their protocols to treat humans understand the importance of examining vectors’ behavior in a variety of comparative assays, including large animal studies, before entering the clinic. The use of well-characterized and well-tested preclinical models such as those of Zhang and colleagues is likely to minimize the risk of an adverse event that would throw the field into another crisis.
Footnotes
Nonstandard abbreviations used: HOXB4, homeobox B4; HSPC, hematopoietic stem and progenitor cell; IL2RG, IL-2 receptor γ; LMO2, LIM domain only 2; SCID-X, X-linked SCID.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 118:1350–1353 (2008). doi:10.1172/JCI35326.
See the related article beginning on page 1502.
1. Sauvageau G., et al. Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. Genes Dev. 1995;9:1753–1765. doi: 10.1101/gad.9.14.1753. [PubMed] [Cross Ref]
2. Perkins A.C., Cory S. Conditional immortalization of mouse myelomonocytic, megakaryocytic and mast cell progenitors by the Hox-2.4 homeobox gene. EMBO J. 1993;12:3835–3846. [PubMed]
3. Thorsteinsdottir U., et al. Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. Mol. Cell. Biol. 1997;17:495–505. [PMC free article] [PubMed]
4. Buske C., et al. Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cells. Blood. 2002;100:862–868. doi: 10.1182/blood-2002-01-0220. [PubMed] [Cross Ref]
5. Schiedlmeier B., et al. High-level ectopic HOXB4 expression confers a profound in vivo competitive growth advantage on human cord blood CD34+ cells, but impairs lymphomyeloid differentiation. Blood. 2003;101:1759–1768. doi: 10.1182/blood-2002-03-0767. [PubMed] [Cross Ref]
6. Baum C., et al. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol. Ther. 2004;9:5–13. [PubMed]
7. Baum C., et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood. 2003;101:2099–2114. doi: 10.1182/blood-2002-07-2314. [PubMed] [Cross Ref]
8. Cavazzana-Calvo M., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669–672. doi: 10.1126/science.288.5466.669. [PubMed] [Cross Ref]
9. Hacein-Bey-Abina S., et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 2002;346:1185–1193. doi: 10.1056/NEJMoa012616. [PubMed] [Cross Ref]
10. Hacein-Bey-Abina S., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2003;348:255–256. doi: 10.1056/NEJM200301163480314. [PubMed] [Cross Ref]
11. Hacein-Bey-Abina S., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415–419. doi: 10.1126/science.1088547. [PubMed] [Cross Ref]
12. Dave U.P., Jenkins N.A., Copeland N.G. Gene therapy insertional mutagenesis insights. . Science. 2004;303:333. [PubMed]
13. Ott M.G., et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 2006;12:401–409. doi: 10.1038/nm1393. [PubMed] [Cross Ref]
14. Seggewiss R., et al. Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood. 2006;107:3865–3867. doi: 10.1182/blood-2005-10-4108. [PubMed] [Cross Ref]
15. Brun A.C., Fan X., Bjornsson J.M., Humphries R.K., Karlsson S. Enforced adenoviral vector-mediated expression of HOXB4 in human umbilical cord blood CD34+ cells promotes myeloid differentiation but not proliferation. Mol. Ther. 2003;8:618–628. doi: 10.1016/S1525-0016(03)00237-5. [PubMed] [Cross Ref]
16. Milsom M.D., et al. Overexpression of HOXB4 confers a myelo-erythroid differentiation delay in vitro. Leukemia. 2005;19:148–153. [PubMed]
17. Pilat S., et al. HOXB4 enforces equivalent fates of ES-cell-derived and adult hematopoietic cells. Proc. Natl. Acad. Sci. U. S. A. 2005;102:12101–12106. doi: 10.1073/pnas.0505624102. [PubMed] [Cross Ref]
18. Zhang X.-B., et al. Differential effects of HOXB4 on nonhuman primate short- and long-term repopulating cells. PLoS. Med. 2006;3:e173. [PMC free article] [PubMed]
19. Zhang X.-B., et al. High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. . J. Clin. Invest. 2008;118:1502–1510.
20. Amsellem S., et al. Ex vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein. Nat. Med. 2003;9:1423–1427. doi: 10.1038/nm953. [PubMed] [Cross Ref]
21. Krosl J., et al. In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein. Nat. Med. 2003;9:1428–1432. [PubMed]
Articles from The Journal of Clinical Investigation are provided here courtesy of
American Society for Clinical Investigation